Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antitumor, monoclonal antibodies | 5833 | None |
| Molecule | Description |
|---|---|
|
Synonyms:
|
Odronextamab is a human IgG4-based bispecific antibody that binds to CD20, a B-cell surface antigen present on normal and malignant B cells and CD3, a T-cell antigen associated with the T-cell receptor complex. Simultaneous engagement of both arms of odronextamab results in formation of a synapse between the T cell and the CD20-expressing cell, resulting in T-cell activation and generation of polyclonal cytotoxic T-cell response, which result in redirected lysis of the targeted cells, including malignant B cells.
|
None
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Aug. 22, 2024 | EMA | Regeneron Ireland Designated Activity Company (DAC) |
None
None
None
None
| Source | Code | Description |
|---|---|---|
| ATC | L01FX34 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES Other monoclonal antibodies and antibody drug conjugates |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Relapsed or refractory follicular lymphoma | indication | 55150002 | |
| Relapsed or refractory large B-cell lymphoma | indication | 109979007 |
None
None
None
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| T-cell surface glycoprotein CD3 | Surface antigen | ANTIBODY BINDING | UNKNOWN | DRUG LABEL | |||||
| B-lymphocyte antigen CD20 | Surface antigen | ANTIBODY BINDING | UNKNOWN | DRUG LABEL |
| ID | Source |
|---|---|
| 1801338-64-6 | SECONDARY_CAS_RN |
| CHEMBL4298084 | ChEMBL_ID |
| DB16684 | DRUGBANK_ID |
| C5421266 | UMLSCUI |
| CHEBI:757503 | CHEBI |
| 11035 | INN_ID |
| 12690 | IUPHAR_LIGAND_ID |
| 8R5CM46UIO | UNII |
| D11534 | KEGG_DRUG |
None